Vaccine Manufacture and Supply – News and Features

The FDA has approved the first COVID-19 vaccine. The vaccine (once known as the Pfizer-BioNTech COVID-19 Vaccine) will now be marketed as Comirnaty, for the prevention of disease in individuals 16 years of age and older.

This article covers the challenges associated with conventional vaccine approaches and elaborates on some of the recent innovations which can help design better vaccines.

Severe acute respiratory syndrome coronavirus-2, the causal agent of the ongoing coronavirus pandemic, has been evolving ever since the first outbreak in December 2019. Researchers believe that rapid vaccination is the most effective strategy to contain the pandemic.

Technology Networks is committed to keeping you updated with the latest research in this space. Here, you'll find a curation of our latest COVID-19 vaccine-related content.

Technology Networks spoke to Hiroshi Kiyono, DDS, PhD, from the Institute of Medical Science at the University of Tokyo who is currently also affiliated with Chiba University and University of California, San Diego, to find out more about MucoRice-CTB, a room-temperature stable oral vaccine being developed using genetically modified rice plants.

A study has shown that total antibody levels appear to start declining from as early as six weeks after complete vaccination and can reduce by more than 50% over 10 weeks.

The lack of equitable access to COVID-19 vaccines undercuts the ethical basis for vaccination “passports” to confer eligibility for domestic and international travel, according to an analysis published in the Journal of Medical Ethics.

Learn how a freezer inventory management software enables biobanks to seamlessly manage & track storage locations of vaccines, ensure effective cold chain management, assuring quality and safe distribution of COVID-19 vaccines.

Science writer Anthony King takes a close look at how each of the authorized COVID-19 vaccines are made, and the challenges faced when working to vaccinate the global population.

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose, and a third dose of the vaccine continues to boost antibodies against SARS-CoV-2.